GUARDaHEART, PULS Cardiac Test And Max International Focus On Prevention, Improved Patient Outcome At American College of Cardiology Scientific Sessions 2016
IRVINE, Calif., April 18, 2016 /PRNewswire-iReach/ -- The GUARDaHEART Foundation, a 501(c)(3) a nonprofit organization, invited the PULS Cardiac TestTM for heart disease, as well as Max International, LLC, to the American College of Cardiology's (ACC) 65th Annual Scientific Session in Chicago to help lead the pursuit of conquering heart disease.
The partnerships at the conference focused on education, detection and prevention at the Patient Engagement Pavilion, the ACC's specialty area showcasing programs, tools, and resources that empower patients, clinicians, and caregivers to work together to achieve measurable improvements in cardiovascular outcomes.
The conference follows a recently published case study by the ACC, where a CCTA test confirmed an elevated risk of Acute Coronary Syndrome originally identified by the PULS Cardiac Test. The PULS Cardiac Test has received significant attention within the medical community as an effective diagnostic tool that allows physicians to identify patients with subclinical, asymptomatic heart disease, who may otherwise be unaware they are at risk of experiencing an acute cardiac event.
"GUARDaHEART and the PULS Cardiac Test fully support the ACC focus on primary prevention," commented Dr. Douglas Harrington, CEO & Medical Director of GD Biosciences, the performing laboratory for the PULS Cardiac Test. "We have demonstrated that a model comprised of education, detection and prevention improves patient outcome and saves lives."
A long time GUARDaHEART partner with them at the ACC event, Max International, is a company dedicated to delivering world-class products designed to support healthy and proactive lifestyles and promote preventive healthcare.
"Max International, LLC is pleased to be a partner with the GUARDaHEART non-profit foundation," Said Scott Nagasawa, Pharm. D. of Max International, "It is becoming increasingly evident that our diets and living a healthy lifestyle are important for healthy aging. By 2030, it is anticipated that 1 in 4 dollars spent will be on healthcare, and prevention must be a major component in reducing future healthcare costs. I have always felt that we allocate too few dollars on prevention, and too much money is being spent for the treatment of preventable diseases."
The American College of Cardiology's annual event hosts some of the best and brightest as speakers and presenters, and allows people from across the industry to share new and exciting information in the field of Cardiology. GUARDaHEART, with partners Max International, and the PULS Cardiac Test, attended the patient pavilion showcasing clinical cases of improved patient outcome based on early, accurate detection.
GUARDaHEART is a 501(c)(3) nonprofit foundation dedicated to fighting heart disease with the mission: "LEARN. DETECT. PREVENT." GUARDaHEART works with strategic partners, healthcare providers, and other non-profit organizations to promote awareness through education and risk detection tools, to ultimately empower preventative action and reduce the risk of heart disease worldwide.
Heart disease is the leading cause of death in the United States, but many are unaware that it is 80% preventable. GUARDaHEART encourages individuals to know their risk of heart disease, and take the necessary steps to maintain or reduce their risk in order to prevent a heart attack.
About Max International, LLC
Max International was founded with a vision to empower people to build a legacy of significant change in their lives and the lives of others. They maintain a long term vision of health and look beyond short term solutions to truly make a positive impact on the global health landscape.
Thanks to the efforts of medicinal chemist Dr. Herbert T. Nagasawa and other experts in scientific research and development, Max International has developed groundbreaking advances in glutathione enhancing products. Their patented compound RiboCeine has been the subject of over 20 independent peer reviewed studies.
About the PULS Cardiac TestTM
The PULS Cardiac Test is a simple blood test that uses breakthrough medical technology to identify individuals with active, yet undetected subclinical Coronary Heart Disease (CHD), who are at risk of experiencing a Heart Attack, and for whom early intervention can help. The test uses 9 clinically-significant protein biomarkers to measure the body's immune system response to arterial injury leading to the formation of unstable cardiac lesions the cause of 75% of all Heart Attacks.
Check out our recent news coverage:
Media Contact: Adam Farragut, Selig Multimedia, (813) 708-1220;7778, firstname.lastname@example.org
News distributed by PR Newswire iReach: https://ireach.prnewswire.com